No headlines found.
Globe Newswire (Wed, 28-Jan 8:00 AM ET)
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Globe Newswire (Tue, 16-Dec 8:30 AM ET)
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100 Supporting NDA Submission
Globe Newswire (Wed, 3-Dec 8:30 AM ET)
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
Globe Newswire (Tue, 25-Nov 8:30 AM ET)
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Globe Newswire (Wed, 12-Nov 7:30 AM ET)
PolyPid's D-PLEX100 Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
Globe Newswire (Thu, 6-Nov 8:30 AM ET)
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Polypid Ltd. - trades on the NASDAQ stock market under the symbol PYPD.
As of February 2, 2026, PYPD stock price climbed to $4.90 with 39,785 million shares trading.
PYPD has a beta of 0.84, meaning it tends to be less sensitive to market movements. PYPD has a correlation of 0.10 to the broad based SPY ETF.
PYPD has a market cap of $49.94 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, PYPD traded as high as $25.69 and as low as $2.30.
PYPD has outperformed the market in the last year with a price return of +63.9% while the SPY ETF gained +16.1%. PYPD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +27.6% and +12.1%, respectively, while the SPY returned +2.6% and +0.5%, respectively.
PYPD support price is $4.39 and resistance is $4.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PYPD shares will trade within this expected range on the day.